




Venetoclax

your ccure api by **Lebsa** and **Selectchemie**



Main Therapeutic Application
ANTINEOPLASTIC

CAS-RN	1257044 - 40 -8
Specification	In House
Documentation	Under Development

Venetoclax (CAS-RN 1257044-40-8) is an antineoplastic agent approved in 2016 by US FDA to treat patients with Chronic Lymphocytic Leukemia (CLL).

Venetoclax is a potent and selective inhibitor of the antiapoptotic protein BCL-2 (B-cell lymphoma). It binds directly to the binding site of the BH3 domain of BCL-2 and thereby displaces proapoptotic proteins with BH3 domains, such as BIM, to initiate permeabilization of the mitochondrial outer membrane (MOMP), caspase activation and programmed cell death.

let us cure together

Cta. de l'Hospitalet, 34,
08940 Cornellà (Barcelona)
+34 93 377 00 51
lebsa@lebsa.com
www.lebsa.com



Selectchemie

Etzelstrasse, 42,
P.O. Box 772, CH-8038 Zürich
+41 44 487 96 11
info@selectchemie.com
www.selectchemie.com

Africa, Asia,
Australia, Canada,
Russia, USA.

Europe (except Russia),
LATAM, Brasil, Morocco,
Bangladesh, Egypt.